These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 6470977)

  • 1. Role of the gut flora in the reduction of sulfinpyrazone in humans.
    Strong HA; Oates J; Sembi J; Renwick AG; George CF
    J Pharmacol Exp Ther; 1984 Sep; 230(3):726-32. PubMed ID: 6470977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New metabolites of sulfinpyrazone in man.
    Dieterle W; Faigle JW; Moppert J
    Arzneimittelforschung; 1980; 30(6):989-93. PubMed ID: 7191279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The site of reduction of sulphinpyrazone in the rabbit.
    Strong HA; Renwick AG; George CF
    Xenobiotica; 1984 Oct; 14(10):815-26. PubMed ID: 6506754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
    Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
    Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative bioavailability of a metoprolol controlled release formulation and a bisoprolol normal release tablet after single oral dose administration in healthy volunteers.
    Deroubaix X; Lins RL; Lens S; Demblon C; Jeanbaptiste B; Poelaert D; Stockis A
    Int J Clin Pharmacol Ther; 1996 Feb; 34(2):61-70. PubMed ID: 8929748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma levels of sulfinpyrazone and of two of its metabolites after a single dose and during the steady state.
    Rosenkranz B; Fischer C; Jakobsen P; Kirstein Pedersen A; Frölich JC
    Eur J Clin Pharmacol; 1983; 24(2):231-5. PubMed ID: 6840173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic parameters of terbutaline in healthy man. An overview.
    Nyberg L
    Eur J Respir Dis Suppl; 1984; 134():149-60. PubMed ID: 6586475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disposition of oral azithromycin in humans.
    Luke DR; Foulds G
    Clin Pharmacol Ther; 1997 Jun; 61(6):641-8. PubMed ID: 9209246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of (S)-warfarin metabolism by sulfinpyrazone and its metabolites.
    He M; Kunze KL; Trager WF
    Drug Metab Dispos; 1995 Jun; 23(6):659-63. PubMed ID: 7587949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Skin penetration of sulfamethoxazole and trimethoprim after oral administration].
    Królicki A
    Ann Acad Med Stetin; 2002; 48():59-73. PubMed ID: 14601469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses.
    Schuppan D; Molz KH; Staib AH; Rietbrock N
    Int J Clin Pharmacol Ther Toxicol; 1981 May; 19(5):223-7. PubMed ID: 7251238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levetiracetam: relative bioavailability and bioequivalence of a 10% oral solution (750 mg) and 750-mg tablets.
    Coupez R; Straetemans R; Sehgal G; Stockis A; Lu ZS
    J Clin Pharmacol; 2003 Dec; 43(12):1370-6. PubMed ID: 14615473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetics and metabolism of sulfinpyrazone.
    Mahony C; Wolfram KM; Nash PV; Bjornsson TD
    Clin Pharmacol Ther; 1983 Apr; 33(4):491-7. PubMed ID: 6831828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man.
    Christensen LA
    Dan Med Bull; 2000 Feb; 47(1):20-41. PubMed ID: 10709142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of the antimalarial drug, AQ-13, in rats and cynomolgus macaques.
    Ramanathan-Girish S; Catz P; Creek MR; Wu B; Thomas D; Krogstad DJ; De D; Mirsalis JC; Green CE
    Int J Toxicol; 2004; 23(3):179-89. PubMed ID: 15204721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of the gut flora in the reduction of sulphinpyrazone in the rat.
    Renwick AG; Evans SP; Sweatman TW; Cumberland J; George CF
    Biochem Pharmacol; 1982 Aug; 31(16):2649-56. PubMed ID: 7138558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys.
    Matsumoto S; Tagawa M; Amejima H; Nakao M; Kagemoto A; Fujii T; Miyazaki H; Sekine Y
    Arzneimittelforschung; 1993 Oct; 43(10):1084-94. PubMed ID: 8267675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of male-female differences in disposition and esterase hydrolysis of ramipril to ramiprilat in healthy volunteers after a single oral dose.
    Vree TB; Dammers E; Ulc I; Horkovics-Kovats S; Ryska M; Merkx ; Ijsbrand
    ScientificWorldJournal; 2003 Dec; 3():1332-43. PubMed ID: 14755115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete bioavailability and lack of food-effect on pharmacokinetics of gliclazide 30 mg modified release in healthy volunteers.
    Delrat P; Paraire M; Jochemsen R
    Biopharm Drug Dispos; 2002 May; 23(4):151-7. PubMed ID: 12015789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.